NKTR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally...

Stats
Dzisiejszy wolumen	558 779
Średni wolumen	2.52M
Kapitalizacja rynkowa	242.38M
EPS	$0 ( 2024-03-04 )
Następna data zysków	( $-0.200 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.910
ATR14	$0.00300 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Deep Track Capital, Lp	Buy	0	Common Stock
2024-02-20	Zalevsky Jonathan	Sell	9 014	Common Stock
2024-02-20	Wilson Mark Andrew	Sell	7 606	Common Stock
2024-02-20	Robin Howard W	Sell	20 033	Common Stock
2023-12-13	Zalevsky Jonathan	Buy	250 000	Stock Option

INSIDER POWER
84.96
Last 97 transactions
Buy: 6 976 063 \| Sell: 637 451

Wolumen Korelacja

Długi: 0.50 (weak)

Krótki: 0.86 (strong)

Signal:(65.532) Same movement expected

Nektar Therapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nektar Therapeutics Korelacja - Waluta/Towar

0.00
( neutral )

-0.04
( neutral )

Nektar Therapeutics Finanse

Annual	2023
Przychody:	$90.12M
Zysk brutto:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2023
Przychody:	$90.12M
Zysk brutto:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2022
Przychody:	$92.06M
Zysk brutto:	$70.42M (76.50 %)
EPS:	$-1.970

FY	2021
Przychody:	$101.91M
Zysk brutto:	$77.01M (75.57 %)
EPS:	$-2.86

Financial Reports:

No articles found.

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.